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Rearrangements involving the MLL gene at chromosome band 11q23 are common in infant acute myeloid leukemias (AMLs).
We recently encountered an infant patient with rapidly progressive AML whose leukemic cells harbored a previously
undescribed MLL rearrangement involving an inversion of 11q [inv(11)(q14q23)]. We used panhandle PCR to determine that
this rearrangement juxtaposed the MLL (Mixed-Lineage Leukemia) gene to the CALM (Clathrin Assembly Lymphoid Myeloid
leukemia) gene at 11q14–q21. The CALM protein participates in recruitment of clathrin to internal membrane surfaces,
thereby regulating vesicle formation in both endocytosis and intracellular protein transport. Intriguingly, CALM has been
identified in other cases of AML as a translocation partner for the AF10 gene, which has independently been found to be an
MLL partner in AML. We identified the MLL-CALM fusion transcript (but not the reciprocal CALM-MLL transcript) in leukemia
cell RNA by RT-PCR. The predicted 1803 amino acid MLL-CALM fusion protein includes amino-terminal MLL domains
involved in transcriptional repression, and carboxy-terminal CALM-derived clathrin-binding domains. The genomic breakpoint
in MLL is in the 7th intron (within the breakpoint cluster region); the corresponding CALM breakpoint is in the 7th CALM intron.
In contrast, breakpoints in CALM-AF10 translocations lie in the 17th–19th CALM introns (30 kb downstream); also, in these
translocations, CALM provides the 5 end of the fusion transcript. Together with its previously recognized association with
AF10 in AML, the identification of CALM as an MLL fusion partner suggests that interference with clathrin-mediated trafficking
pathways may be an underappreciated mechanism in leukemogenesis. © 2003 Wiley-Liss, Inc.
INTRODUCTION
Acute myeloid leukemia (AML) accounts for ap-
proximately 15 to 20% of all cases of childhood
leukemia (Golub et al., 1997). In particular, AML
constitutes the most frequent type of congenital
leukemia. In spite of improvements in understand-
ing some of the molecular mechanisms involved in
AML pathogenesis, fewer than 40–50% of newly
diagnosed children with AML are cured.
Although the specific factors that lead to myeloid
leukemogenesis remain unknown, a number of
chromosomal abnormalities have been described in
association with AML. Translocations involving
band q23 of the long arm of chromosome 11
(11q23) are seen in 5–6% of all AML cases, as well
as in 5–10% of all acute lymphoblastic leukemias
(ALLs). Strikingly, the frequency of 11q23 trans-
locations is significantly higher in AML in infants
(50%), and also in infant ALL (80%) (Felix and
Lange, 1999). The presence of 11q23 transloca-
tions correlates with a very poor prognosis (Drey-
ling et al., 1998). In 1993, it was determined that
the MLL (Mixed-Lineage Leukemia) gene at this
locus is involved in nearly all 11q23 translocations
(Thirman et al., 1993). The MLL gene encodes for
a large, complex transcription factor, and transloca-
tions involving MLL result in the formation of
novel hybrid or chimeric genes, whose protein
products are thought to play a key role in leuke-
mogenesis.
To date, there have been more than 30 gene
fusion partners documented for MLL (Ayton and
Cleary, 2001a,b). Many of these genes encode for
nuclear transcription factors; for example, the AF10
gene at 10p13, which is involved in t(10;11)(p13;
q23) translocations in AML-M4 and AML-M5, en-
codes for a zinc finger transcription factor (Beverloo
et al., 1995; Chaplin et al., 1995). Of note, AF10 is
one of the few MLL fusion partners that have been
found to be involved in a translocation with another
gene in both myeloid and lymphoid malignancies
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(Lillington et al., 1998). Specifically, AF10 is fused
to the Clathrin Assembly Lymphoid Myeloid leu-
kemia (CALM) gene at 11q14–q21 in t(10;11)(p13;
q14) translocations (Dreyling et al., 1996, 1998).
The CALM gene encodes a 1956-bp cDNA and a
predicted 652 amino acid (aa) protein product that
binds to clathrin, which mediates vesicle formation
in both endocytosis and intracellular protein trans-
port through the Golgi network (Tebar et al., 1999;
Kim et al., 2000). The CALM protein is thought to
participate in recruitment of clathrin to internal
membrane surfaces, thereby regulating vesicle for-
mation (Tebar et al., 1999). Leukemias with
CALM– AF10 translocations are extremely aggres-
sive and are associated with a very poor prognosis
(Bohlander et al., 2000). The disruption of normal
CALM function by the CALM–AF10 fusion pro-
tein may significantly alter the dynamics of clath-
rin-mediated growth factor receptor turnover, and
potentially alter the sensitivity of cells to external
growth factors (Bohlander et al., 2000). To date,
although the precise roles of the reciprocal gene
fusion products AF10-CALM and CALM-AF10 in
leukemogenesis have not been firmly established
(Silliman et al., 1998; Kumon et al., 1999;
Bohlander et al., 2000; Carlson et al., 2000), the
involvement of the CALM protein implicates per-
turbed vesicle trafficking as having a previously
underappreciated role in leukemogenesis (Bohlander
et al., 2000).
We recently encountered a pediatric patient with
rapidly progressive AML whose leukemic cells
demonstrated a previously unidentified MLL rear-
rangement involving an inversion within 11q. This
rearrangement juxtaposed the MLL gene to the
CALM gene at 11q14–q21. This is the first instance
of a fusion gene involving MLL and CALM, and the
implications of this novel rearrangement in my-
eloid leukemogenesis are discussed.
MATERIALS AND METHODS
Patient
A 12-week-old Caucasian female infant with fe-
ver, congestion, and rhinorrhea developed signifi-
cant respiratory distress. On physical examination,
hepatosplenomegaly was present and multiple pe-
techiae were noted. The initial white blood cell
(WBC) count was 272,000/L, hematocrit was
13%, and the platelet count was 10,000/L. The
peripheral blood smear showed extreme hypercel-
lularity with mature and immature monocytes and
granulocytes; increased eosinophils; nucleated red
blood cells; and two populations of blasts, one
larger with increased cytoplasm and one smaller.
The morphologic pattern was suggestive of either
juvenile myelomonocytic leukemia (JMML) or
AML. Immunophenotyping of the peripheral
blood revealed a majority of cells with phenotypic
features of mature monocytes [CD11C (98.9%),
CD13 (88.1%), CD14 (88.6%), CD33 (97.1%), and
CD56 (51.1%)]. Evaluation of the bone marrow
indicated 100% cellularity, with a monotony of the
neoplastic cell population, and periosteal involve-
ment by neoplastic cells. A 300-cell differential
count of the bone marrow aspirate smear revealed
a high percentage of blasts (19.6%) and promono-
cytes (10%), with evidence of monocytic differen-
tiation, as demonstrated by alpha naphthyl bu-
tyrate esterase and myeloperoxidase. These
findings fulfilled the FAB criteria for acute mono-
cytic leukemia (M5b), with a significant compo-
nent of monocytic differentiation.
Leukapheresis was performed on a single occa-
sion to decrease the tumor cell burden, and imme-
diately reduced the WBC to 163,200/L. Over the
next 4 days, without additional therapy, the WBC
fell to 70,000/L (where it remained until the 10th
hospital day). At the same time, the differential
WBC count showed a dramatically higher percent-
age of monocytes (42–73%) and monocytoid blasts
(16–36%). The patient developed respiratory fail-
ure (requiring intubation) and renal failure (neces-
sitating continuous veno-venous hemodialysis).
Once a diagnosis of AML was confirmed, hemody-
namic and respiratory instability precluded chemo-
therapy initiation with high-dose cytosine arabino-
side. On the 10th hospital day, the peripheral WBC
began to increase, and chemotherapy was initiated,
despite ongoing multiorgan system failure. On the
following day, the patient sustained prolonged hy-
potensive episodes with bradycardia and brain-
stem herniation. Support was withdrawn, and the
patient expired.
Cytogenetic Analysis and Fluorescence In Situ
Hybridization (FISH)
Direct and 24-h cultures of leukemic cells with-
out mitogens were prepared by use of standard
techniques from bone marrow, peripheral blood,
and leukapheresis samples obtained before chemo-
therapy. Slides with metaphase cells were banded
by a trypsin–Giemsa technique; a total of 20 cells
from all cultures were analyzed.
FISH with the MLL gene probe (Vysis, Downers
Grove, IL) was performed following the proce-
dures recommended by the manufacturer. The
MLL “break-apart” probe consists of a 350-kb por-
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tion centromeric of the MLL gene breakpoint clus-
ter region labeled with SpectrumGreen and a
190-kb portion telomeric of the breakpoint region
labeled with SpectrumOrange. A yellow fusion sig-
nal is produced by the juxtaposition of the probes
on a normal MLL gene; distinct orange and green
signals are observed when a rearrangement involv-
ing MLL is present. A DAPI (4-6-diamidino-2-
phenylindole) counterstain is used to visualize
interphase nuclei and to identify metaphase chro-
mosomes. Slides were examined using a Leica
DMRA fluorescence microscope (Leica, Deerfield,
IL) equipped with a filter set, including Spectrum-
Red/Green dual-band pass and DAPI filters and
imaged with a CCD camera using the CytoVysion
software system (Applied Imaging, Santa Clara,
CA). A total of more than 300 interphase cells and
10 metaphase cells were analyzed from two hybrid-
izations, which included a negative control.
cDNA Panhandle PCR
The published technique of Megonigal et al.
(2000a,b) was used with 1 g of leukemia cell-
derived total RNA. After first-strand cDNA synthe-
sis by use of MLL–random hexamer oligonucleo-
tides (MLLRH: 5-CCTGAATCCAAACAGGCCA
CCACTCCAGCTTCNNNNNN-3), second-strand
stem-loop generation was performed. After nested
PCR amplification (first with primers MLP1: 5-
TCCTCCACGAAAGCCCGTCGAG-3 and MLP2:
5-TCAAGCAGGTCTCCCAGCCAGCAC-3, then
with primers MLP3: 5-GGAAAAGAGTGAAGA-
AGGGAATGTCTCGG-3 and MLP4: 5-GTG-
GTCATCCCGCCTCAGCCAC-3), panhandle PCR
products were subcloned by recombination PCR
into the pUC19 vector in MAX efficiency DH5
cells (Gibco BRL, Gaithersburg, MD). Subclones
containing suitable products were identified by
PCR (using primers MLP3 and MLP4), and DNA
sequencing was performed using the fluorescent
dideoxy terminator method on a PE/Abd 373a au-
tomated DNA sequencer at The University of
Michigan DNA Sequencing Core Facility.
Reverse Transcriptase–Polymerase Chain Reaction
(RT-PCR)
A 1 g sample of total leukemic cell RNA was
reverse-transcribed with SuperScript II (Invitrogen
Life Sciences, Carlsbad, CA). The resulting first-
strand cDNA was amplified by use of a Perkin–
Elmer GeneAmp 2400 Thermocycler (Applied
Biosystems/Perkin–Elmer, Foster City, CA) with















GACCAGTGCTTGCCAGG-3), HF Taq polymer-
ase (Roche, Indianapolis, IN), and nucleotide
mixtures. Initial denaturation was at 94°C for 1 min,
followed by 30 cycles of 94°C for 10 sec, annealing at
56°C for 30 sec, and extension at 68°C for 2 min, with
5 sec added per cycle, and a final extension step at
68°C for 7 min.
Long-Range PCR for Detection of Genomic
Breakpoint
The Expand 20 kbPLUS PCR System (Roche)
was used with 5-MLL and 3-CALM specific primers
(MLLEx5F1, from MLL exon 7; and CALMEx9R,
from CALM exon 9) to amplify genomic DNA from
leukemic cells. Amplifications were performed in the
absence or presence of DMSO (5 or 10% final con-
centration), and products were cloned into the
pCRII-TOPO TA cloning vector (Invitrogen, Carlsbad,





CCCTTCCTTTTGTGACCTC-3) were then used
to confirm the breakpoint under the PCR amplification
conditions defined above.
Guthrie Card PCR Analysis
The neonatal blood spot procured on the pa-
tient’s second day of life was obtained from the
State of Michigan Department of Community
Health. Genomic DNA was amplified from this
Guthrie card using a modification of a procedure
developed by Makowski et al. (1995). Briefly, an
office supply hole puncher was used to produce a
1
2
-in.-diameter punch, which was further cut into
four equivalent segments. Each segment was incu-
bated in 1 mL of ddH2O twice for 30 min, then
added directly to PCR amplification reactions as
described above. PCR amplification cycles in-
cluded an initial 94°C 10-min incubation, followed
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by 37 cycles of denaturation at 94°C (15 sec), an-
nealing at 56°C (30 sec), and extension at 72°C
(150 sec), followed by a 7-min extension at 72°C.
Amplifications were repeated four times with
punches from different Guthrie card sections.
Data Analysis
Sequence data were analyzed using MacVector
6.5.3 and Assemblylign (Accelrys, San Diego, CA).
BLAST and BLASTX searches were performed at
http://www.ncbi.nlm.nih.gov.
RESULTS
Cytogenetics and FISH Identify a Novel 11q
Rearrangement
A paracentric inversion of the long arm of chro-
mosome 11, inv(11)(q14q23), was observed in all 20
metaphase cells examined by standard cytogenetic
analysis (Fig. 1A). No other abnormal chromo-
somes were observed. Metaphase FISH confirmed
that the inversion split the MLL gene, moving the
centromeric 5 region to band 11q14, whereas the
3 region remained in band 11q23 (Fig. 1B). Inter-
phase nuclei with normal MLL fusion signals were
observed in 41.3% (124/300) of cells examined
from a peripheral blood sample, indicating that the
rearrangement is an acquired cytogenetic abnor-
mality.
Identification of an MLL-CALM Fusion Transcript
by cDNA Panhandle PCR
We used the technique of cDNA panhandle
PCR (Megonigal et al., 2000a,b) to identify hybrid
transcripts containing the MLL gene. cDNA gen-
erated from total RNA resulted in panhandle prod-
ucts of various sizes, and recombination PCR
yielded several hundred subclones, of which 65
were selected for further PCR analysis. Eight rep-
resentative clones containing inserts, ranging from
250 to 2500 bp, were sequenced. Clones with
smaller inserts included a sequence from MLL ex-
ons 5 and 6, followed by 60–110 bp of MLL exon 5,
then 60–70 bp of MLL exon 5 in reverse orienta-
tion, consistent with previously described exon
scrambling (Megonigal et al., 2000a). These were
not studied in any further detail. Five remaining
clones contained inserts that ranged in size from
1500 to 2500 bp, and all included a sequence that
stopped abruptly after MLL exon 7, sharing an
identical sequence thereafter (Fig. 2A). BLAST
analysis of the sequence immediately following
MLL exon 7 indicated 100% identity with the hu-
man CALM gene, also known as CLTH (GenBank
accession no. U45976/XM_006305). The human
CALM cDNA coding sequence is 1956 bp, and the
predicted 652-aa CALM protein plays a role in
regulation of vesicle formation by recruiting clath-
rin to internal membrane surfaces (Tebar et al.,
1999). The full-length MLL-CALM transcript is
5409 bp, including 4218 bp of MLL sequence (MLL
exons 1–7) and 1191 bp of CALM sequence, corre-
sponding to CALM exons 8–20 (GenBank accession
no. AF477006). The predicted 1803-aa MLL-CALM
fusion protein (Fig. 2B) includes MLL-derived
A-T hooks and a repression domain, and a CALM-
derived clathrin-binding domain.
Figure 1. Cytogenetics and FISH from representative leukemic cells.
A: GTG-banded chromosomes and ideograms depicting the rearrange-
ment of chromosome 11. B: Metaphase cell from the patient hybridized
with the MLL FISH probe. The inverted chromosome (long arrow) has
a split in MLL, which separates into green (centromeric) and red
(telomeric) signals, whereas the normal chromosome 11 homolog
(short arrow) has a yellow fusion signal.
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Confirmation of MLL-CALM Transcript in
Leukemic Cells by RT-PCR
The presence of the MLL-CALM fusion tran-
script in leukemia cell RNA was confirmed by
RT-PCR using 5-MLL- and 3-CALM-specific
primers (Fig. 3, lanes b and c). We also used prim-
ers from the 5 end of CALM and the 3 end of MLL
to demonstrate that the reciprocal CALM-MLL
fusion transcript is not present in the patient’s
leukemia-derived RNA (Fig. 3, lane f). In contrast,
mRNAs from both native MLL and CALM, presum-
ably derived from the unaffected chromosome 11,
are detectable (Fig. 3, lane a and lanes d and e).
Determination of Genomic Breakpoint
To determine the genomic breakpoint that re-
sults in the MLL-CALM fusion transcript, we used
long-range PCR with 5-MLL- and 3-CALM-spe-
cific oligonucleotide primers and leukemia-derived
genomic DNA, and amplified a 6.2-kb product
(data not shown). DNA sequencing analysis (Fig.
4A) revealed that the breakpoint in MLL lies in the
7th intron (444–446 bp from the end of MLL exon
7) within the breakpoint cluster region, a well-
characterized region of chromosome instability
(Felix et al., 1998; Felix and Lange, 1999). The
breakpoint within CALM lies in the 7th CALM
Figure 2. Panhandle PCR identifies CALM as an MLL fusion partner.
A: Subclone sequence analysis identified CALM as an MLL partner in five
separate recombination PCR-generated subclones (GenBank accession
no. AF477006). B: Predicted full-length MLL-CALM fusion protein.
Schematic of native MLL (top) and CALM (bottom) proteins, and pre-
dicted 1803-aa MLL-CALM fusion protein (middle). The fusion protein
retains the three AT-hooks (AT1–3), nuclear localizing sequence (NLS),
and CXXC domains of MLL, but lacks PHD, Basic (BR), and SET
domains. The fusion protein also includes the putative CALM clathrin-
binding domains (CBD), but not the phosphatidylinositol phosphate
(PIP)–binding domain.
Figure 3. Identification of MLL-CALM transcripts in leukemic cells by
RT-PCR. RT-PCR analysis of leukemia cell RNA by use of MLL- and
CALM-specific primers. Amplification with primers for native MLL
(MLL4159 and MLLEx9R1055, lane a) and CALM (CALMF713 and
CALMR985, lane d; CALMF713 and CALMR1094, lane e) transcripts yields
products of the expected size, as do primers for the hybrid MLL-CALM
transcript (MLL4159 and CALMR985, lane b; and MLL4159 and CALMR1094,
lane c). No product was detected using a forward CALM primer together
with a reverse MLL primer (CALMF713 and MLLEx9R1055, lane f), indicating
the absence of the CALM-MLL transcript.
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intron (1525–1527 bp upstream of CALM exon 8),
but precise assignment of breakpoint positions was
not possible because of the presence of identical
5-CT-3 sequences in MLL and CALM (GenBank
accession no. AF477007). This rearrangement results
in an MLL–CALM fusion transcript that positions
MLL exon 7 immediately upstream of CALM exon 8.
By using oligonucleotide primers flanking the puta-
tive breakpoints in MLL intron 7 and CALM intron 7,
we were able to confirm the genomic breakpoint in
DNA derived from the diagnostic leukemia speci-
men (Fig. 4B). Furthermore, genomic PCR per-
formed with several sets of 5-CALM and 3-MLL
primers failed to yield a product (data not shown),
consistent with the absence of a CALM-MLL mRNA
transcript (Fig. 3, lane f). The MLL-CALM fusion
gene was also present at least 10 weeks earlier, as
evidenced by the presence of an identical PCR am-
plification product in the Guthrie spot blood obtained
on the second day of life (Fig. 4C, lane b). Although
the PCR reaction is not quantitative, the intensity of
the MLL-CALM PCR product in Guthrie spot DNA
(lane b) relative to that in the diagnostic leukemia
specimen (lane d) is clearly diminished, in compari-
son with MLL products amplified from the same
specimens (lanes a and c).
Genomic Structure of Human CALM: A Novel
Exon and Alternatively Spliced Transcripts
Based on the draft genomic sequence of hu-
man chromosome 11 (GenBank accession no.
NT_001984), the human CALM gene spans ap-
proximately 110 kb and is composed of 20 exons
(Fig. 5A). Sequencing analysis of the clones de-
rived from our patient indicates the presence of a
novel exon near the 3 end of CALM. Two of the
initially isolated MLL-CALM clones, with 1600- and
1800-bp inserts, included an identical 24-bp insert
that was not present in the human CALM se-
quence, or in rat CALM (GenBank accession nos.
AF041373/AF041374). This sequence was, how-
ever, present in the murine CALM cDNA (Gen-
Bank accession no. BC011470) (Fig. 5B). RT-PCR
by use of CALM-specific primers with both leuke-
mia cell RNA and control, non-leukemia RNA in-
dicated the presence of transcripts both with and
without the 24-bp insert (data not shown). Because
a 24-bp insert may be spliced out while still main-
taining the reading frame of the remainder of the
protein, this sequence represents a previously un-
described human CALM exon (17a; GenBank ac-
cession no. AF477006). Indeed, a survey of the
available human chromosome 11 genomic se-
quence (GenBank accession no. NT_009184) indi-
cated that the 24-bp sequence was present within
the CALM gene between exons 17 and 18 (nucle-
otides 1059895–1059918) (Fig. 5A), flanked by AG
and GT splice acceptor and donor sites (Fig. 5C).
The functional significance of the CALM protein
that includes the 8-aa NGMHFPQY sequence re-
Figure 4. Definition of genomic breakpoints within MLL and CALM
introns. A: Genomic sequences within the 7th introns of MLL (upper)
and CALM (lower) are indicated, with homologies to the derivative
sequence (middle) indicated by colons. The genomic breakpoint within
the MLL gene is 444, 445, or 446 bp from the beginning of intron 7, and
the CALM breakpoint is 1527, 1526, or 1525 bp upstream of the end of
intron 7. Identical 5-CT-3 sequences in MLL and CALM (outlined)
preclude a more precise assignment of breakpoint positions (GenBank
accession no. AF477007). B: PCR amplification by use of genomic DNA
as a template with forward and reverse intron 7 MLL and CALM primers
yields a band from leukemia cell–derived DNA (lanes a–d), but not
control DNA (lanes e–h). Primers in lanes a and e: MLLINT7-450 and
CALMINTR-695; lanes b and f: MLLINT7-450 and CALMR946; lanes c
and g: CALMINT7BK562 and CALMINTR-695; lanes d and h:
CALMINT7BK562 and CALMR946. C: PCR amplification by use of
genomic DNA derived from neonatal Guthrie spot (GS), in comparison
with diagnostic leukemia cells (DL), control non-leukemic cells (C), and
no DNA control (Neg). Primers used were specific for MLL (lanes a, c,
e, and g indicated by M: MLL4159 and MLLEx8R942) or MLL-CALM (lanes
b, d, f, and h indicated by *: MLLINT7-450 and CALMINTR-695). Gel
shown is representative of four amplifications performed with four
different GS punches. Arrow indicates MLL-CALM band in GS DNA.
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mains to be determined. Of note, this region is
within the putative CALM carboxy-terminal clath-
rin-binding domain.
Finally, RNA derived from our patient includes
transcripts that lack 21 bp of sequence at the be-
ginning of CALM exon 13 (data not shown). This
region is missing from rat CALM but is present in
murine CALM. It is also present in the human
genomic chromosome 11 sequence, and does not
constitute a distinct exon because it is contiguous
with the remainder of exon 13. However, because
the last 2 bp of this region correspond to an AG 3
splice acceptor site, it is possible that they consti-
tute a cryptic splice site that is used to generate
some CALM transcripts. Indeed, this region bears a
high degree of similarity to the consensus sequence
of 3 splice acceptor sites (Shapiro and Senapathy,
1987). A similar cryptic splice site at the beginning
of exon 15 could account for the alternative splice
product detected in the original description of
CALM (Dreyling et al., 1996).
DISCUSSION
Translocations involving the MLL gene play a
role in the pathogenesis of both lymphoid and
myeloid leukemias, particularly those that develop
in infants. Although more than 30 MLL partner
genes have been identified (Ayton and Cleary,
2001b), the precise mechanisms by which most
MLL fusion proteins contribute to leukemic trans-
formation remain unknown. In this report, we de-
scribe the use of panhandle PCR to identify CALM
as a novel translocation partner for the MLL gene in
an infant with AML. The patient’s leukemia was
extremely aggressive, and was characterized by an
unusual JMML-like phenotype. The MLL-CALM
translocation was present in DNA derived from the
neonatal Guthrie spot, indicating a prenatal origin
of the leukemic clone. We have documented the
genomic structure of human CALM for the first
time, and identified a novel human CALM exon, as
well as several alternatively spliced CALM iso-
forms. Because CALM has been identified as a
translocation partner for AF10 in leukemias with
t(10;11)(p13;q14), the involvement of CALM in
separate translocations with both MLL and AF10
suggests that CALM-dependent endocytosis path-
ways may be important in leukemogenesis.
The CALM gene is ubiquitously expressed
(Dreyling et al., 1996), and encodes for a 652-aa
Figure 5. Genomic organization of human CALM. A: Schematic
representation of exon structure of the human CALM gene, derived
from available chromosome 11 sequence. The locations of the break-
point within CALM as well as the novel 24-bp exon (exon 17a) are
indicated. Numbers below the bar indicate distance (in bp) from CALM
ATG. B: Alignment of MLL-CALM sequence with human, rat, and mouse
CALM cDNA sequences indicates the presence of a 24-bp insert in both
MLL-CALM and mouse CALM, but not human or rat cDNAs. C:
Genomic sequence flanking putative human CALM exon 17a (uppercase),
with flanking intron sequence (lowercase) indicating presence of consen-
sus splice donor and acceptor sites (boxed).
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protein with homology to AP180, a synaptic protein
involved in clathrin assembly and endocytic vesicle
formation. The full-length CALM protein is pri-
marily associated with cellular membrane fractions,
and co-localizes with clathrin in endocytic pits (Te-
bar et al., 1999). Binding to clathrin is mediated
primarily by carboxy-terminal CALM domains (aas
414–652) (Tebar et al., 1999), whereas a lysine-rich
amino-terminal ENTH homology domain is re-
sponsible for binding to membrane inositol
polyphosphates (Ford et al., 2001; Itoh et al., 2001).
CALM also contains amino-terminal proline-rich
sequences that direct binding to the SH3 domain
of PLC1 (Kim et al., 2000; Kim and Kim, 2001).
Together with carboxy-terminal DPF and NPF
motifs that may mediate binding to AP-2 and
Eps15 homology (EH) domains, respectively (San-
tolini et al., 1999; Ford et al., 2001), these features
suggest a role for CALM in tethering clathrin and
its adaptor proteins to membranes during the early
stages of endocytic vesicle formation. That CALM
plays a definitive role in endocytic vesicle forma-
tion is demonstrated by the ability of overex-
pressed CALM to interfere with endocytosis of
receptors for both transferrin and epidermal growth
factor (Tebar et al., 1999). CALM overexpression
also results in loss of clathrin accumulation in the
trans-Golgi network (Tebar et al., 1999). Thus,
perturbation of normal CALM activity might inter-
fere with endocytosis.
Intriguingly, a transcriptional regulatory domain
has been described in the carboxy-terminal region
of CALM (Bohlander and Bartels, 1997), and
CALM has recently been shown to act as a tran-
scriptional activator in GAL4-based transcriptional
assays (Vecchi et al., 2001). The same report indi-
cated that the CALM protein also undergoes nu-
cleocytoplasmic shuttling (Vecchi et al., 2001), sug-
gesting that, in addition to its role in endocytosis,
CALM might also participate in transcriptional reg-
ulation.
The CALM gene was first described as a translo-
cation partner for AF10 in the U937 monocytic cell
line (Dreyling et al., 1996, 1998). Notably, AF10
was initially identified as an MLL translocation
partner in AML (Chaplin et al., 1995), and it is one
of only two MLL partner genes [the other being
CBP (Borrow et al., 1996)] that are known to par-
ticipate in translocations with genes other than
MLL (Ayton and Cleary, 2001b). Subsequent inves-
tigations have confirmed the presence of CALM-
AF10 transcripts in a total of 25 patients, including
12 myeloid leukemias, 6 T-cell leukemias, 4 T-cell
lymphomas, and 3 mixed-lineage leukemias (Koba-
yashi et al., 1997; Dreyling et al., 1998; Silliman et
al., 1998; Kumon et al., 1999; Narita et al., 1999;
Bohlander et al., 2000; Carlson et al., 2000; Salmon-
Nguyen et al., 2000; Jones et al., 2001). In all
CALM-AF10 translocations, the breakpoints within
the CALM gene lie in the 17th–19th introns (Silli-
man et al., 1998; Kumon et al., 1999; Narita et al.,
1999; Bohlander et al., 2000; Carlson et al., 2000),
resulting in CALM-AF10 transcripts that include
almost the entire 5 CALM coding sequence, with
only a small portion of 3 AF10 sequence. In con-
trast, the CALM breakpoint in the MLL-CALM
translocation reported here falls in the 7th CALM
intron, nearly 30 kb upstream. As a result, CALM
contributes nearly 400 carboxy-terminal aas to
MLL-CALM. The reciprocal CALM-MLL fusion
transcript was not detectable, and genomic PCR
failed to identify products indicative of a derivative
CALM-MLL genomic translocation. However, the
absence of CALM-MLL transcript/sequence might
be attributed to a concomitant deletion of 5 CALM
genomic sequence; this remains to be definitively
shown. Because reciprocal AF10-CALM transcripts
are detected in only a minority of t(10;11) translo-
cations, the conservation of carboxy-terminal
CALM domains in both MLL-CALM and CALM-
AF10 indicates that perturbation of functions de-
pendent on motifs in this region likely plays a role
in leukemogenesis.
As for nearly all other MLL translocations, the
MLL breakpoint in the MLL-CALM translocation
gene (in MLL intron 7) is within the 8.3-kb break-
point cluster region encompassing exons 5 to 11.
The MLL-CALM translocation results in a novel
hybrid protein that contains MLL amino-terminal–
derived AT-hook DNA binding and transcriptional
repression motifs, but lacks MLL carboxy-terminal
transcriptional activation and SET domains. CALM
contributes nearly 400 aas to the carboxy terminal
of MLL-CALM, containing the primary clathrin-
binding domain, as well as the putative CALM
transactivation domain. Nuclear localization of the
hybrid MLL-CALM protein might disrupt normal
MLL function by binding to DNA and misregulat-
ing the expression of downstream MLL targets
that are important in hematopoietic cell develop-
ment (Caslini et al., 2000). At the same time, cyto-
plasmic localization of the protein might perturb
clathrin-dependent endocytic pathways because of
the presence of CALM clathrin-binding motifs, in
the absence of amino-terminal CALM regulatory
domains. Thus, the retention of key MLL and
CALM domains may result in novel functional
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activities that potentially alter both nuclear and
cytoplasmic processes.
The conservation of amino-terminal MLL tran-
scriptional regulatory domains in all MLL fusion
proteins indicates that gain of MLL function plays
a critical role in leukemogenesis (Ayton and Cleary,
2001a,b). However, differences in the latency of
different MLL-associated leukemias are likely re-
lated to disruption of partner function. MLL fusion
proteins in leukemias with a short latency [e.g.,
MLL-AF9 (Corral et al., 1996), MLL-AF10 (Ayton
and Cleary, 2001b), MLL-ENL (Lavau et al., 1997;
Slany et al., 1998a,b)] are thought simultaneously
to disrupt MLL-independent pathways through ei-
ther loss or gain of partner protein function (DiMa-
rtino and Cleary, 1999; Ayton and Cleary, 2001b).
How might expression of the MLL-CALM fu-
sion protein perturb clathrin-dependent endocyto-
sis and contribute to leukemogenesis? Endocytosis
of receptor-bound growth factors by clathrin-coated
vesicles is one mechanism by which growth factor
signaling is attenuated (reviewed in Floyd and De
Camilli, 1998; Di Fiore and Gill, 1999). For exam-
ple, epidermal growth factor (EGF)–dependent
cell proliferation is enhanced in endocytosis-defec-
tive cells, suggesting that impaired clathrin-medi-
ated endocytosis of EGF–EGF receptor (EGFR)
complexes prolongs EGFR signaling (Vieira et al.,
1996). Because MLL-CALM contains a clathrin-
binding site, but lacks the amino-terminal CALM
domains putatively involved in tethering to mem-
brane inositol polyphosphates, the fusion protein
might act in a dominant-negative fashion to inter-
fere with endocytosis of proliferation-promoting
hematopoietic growth factors. Disrupted clearance
of receptor-bound factors could then result in per-
sistent signaling and cell proliferation. The im-
paired attenuation of growth factor signaling
caused by MLL-CALM protein expression, to-
gether with altered MLL function (as a result of
loss of carboxy-terminal MLL domains), might
have contributed to the aggressive leukemia seen
in this infant.
In addition to CALM, other genes whose protein
products participate in endocytosis have been iden-
tified as targets of chromosomal rearrangements in
myeloid leukemia. The human AF-1p and EEN
genes (homologs of murine Eps15 and SH3p8, re-
spectively) encode for components of clathrin-
coated pits, and both genes are involved in trans-
locations with MLL (Bernard et al., 1994; So et al.,
1997, 2000). The ABI-1 gene, whose protein prod-
uct interacts with two other key components of
clathrin-dependent vesicles (synaptojanin and dy-
namin), has also been described as an MLL trans-
location partner (Taki et al., 1998; So et al., 2000).
In addition, other tumor-suppressor and cancer-
predisposition genes are linked to endocytic path-
ways (Floyd and De Camilli, 1998; Di Fiore and
Gill, 1999). The ataxia-telangiectasia (ATM) can-
cer-predisposition gene interacts with -adaptin, a
component of the AP2 clathrin adaptor (Lim et al.,
1998). A member of the -adaptin family, BAM22
(Peyrard et al., 1994), is a candidate meningioma
tumor-suppressor gene. Together with these obser-
vations, the current identification of CALM as an
MLL fusion gene partner implicates clathrin-de-
pendent vesicle pathways in the process of malig-
nant transformation.
The extremely short latency and aggressive na-
ture of overt leukemia in this patient suggest the
likelihood that transforming events occurred in
utero. Translocations involving MLL and AF4 have
been “backtracked” to birth (Gale et al., 1997;
Rowley, 1998), and specific in utero exposures are
thought to contribute to leukemogenesis (Ross,
1998, 2000; Strick et al., 2000; Alexander et al.,
2001). Our demonstration that the MLL-CALM fu-
sion was present in the neonatal Guthrie blood spot
indicates a prenatal initiation of this patient’s leu-
kemia. Although PCR amplification is not quanti-
tative, the reduced intensity of the MLL-CALM
product relative to MLL in the Guthrie card sam-
ple, compared to that of the diagnostic leukemia
specimen (Fig. 4C), suggests a relatively small
number of cells harboring the translocation at birth.
Whether subsequent transforming events (in addi-
tion to the MLL-CALM translocation) contributed
to leukemogenesis remains unknown.
Finally, we have documented the human CALM
genomic structure, and have identified a novel hu-
man CALM exon (17a). We have also identified an
alternatively spliced CALM transcript that would
result in a protein lacking 7 amino acids in the
CALM carboxy-terminus. Previous studies of
CALM-AF10 have indicated alternative splicing of
CALM. Specifically, CALM exons 13, 15, and 18 are
spliced out of some CALM and CALM-AF10 tran-
scripts (Dreyling et al., 1996; Silliman et al., 1998;
Kumon et al., 1999). The functional significance of
CALM and MLL-CALM transcripts bearing or lack-
ing exon 17a, or any of the other alternatively
spliced transcripts, remains to be determined.
The significance of identifying an MLL-CALM
fusion gene in infant AML is threefold. This is the
first instance in which the CALM gene has been
identified as a partner for the MLL gene. Although
several defined MLL partners are transcription fac-
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tors, a substantial number have other distinct func-
tions. The fact that this patient’s leukemia was
rapidly progressive suggests that disruption of nor-
mal CALM function might contribute in a specific
way to leukemogenesis. Second, the CALM gene
was originally identified as a partner for the AF10
gene in both myeloid and lymphoid leukemia. Be-
cause AF10 was first identified as an MLL partner,
the description of MLL– AF10, AF10-CALM, and
now MLL-CALM translocations suggests that path-
ways involving all three of these genes are impor-
tant in both leukemogenesis and normal hemato-
poiesis. Third, the specific role of the CALM gene
product in clathrin-mediated endocytosis and ves-
icle transport suggests previously underappreciated
mechanisms that might contribute to leukemogen-
esis. In particular, disruption of normal endocytosis
and vesicle transport may result in aberrant signal
transduction. Future studies will investigate the
ability of the MLL-CALM fusion protein to trans-
form hematopoietic progenitors, and elucidate the
mechanisms by which this might occur.
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